Standard Health Record FHIR Implementation Guide

SHR BrcaReceptorStatusCS CodeSystem

Classification of receptor status in breast cancer.

This code system http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS defines the following codes:

CodeDisplayDefinition
luminal_A Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.
luminal_B Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2.Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2.
HER2_positive Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2.Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2.
Triple_negative Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy.Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy.
Downloads: XML, JSON, Turtle

References

This code system is used by the following value sets: